Personal and health care giant Johnson & Johnson has announced plans to acquire privately-held Aragon Pharmaceuticals in a deal that could reach $1 billion, according to reports. The acquisition is a strategic move for Johnson & Johnson into the market for pharmaceutical drugs that specialize in fighting diseases caused and driven by hormones. Reports say the deal between the parties includes a $650 million payment upfront as well as payments of $350 million in increments as the company reaches certain milestones. Aragon will reportedly separate the rest of its assets into a new business. Aragon is currently in the mid-stage of development of a drug to fight prostate cancer. The deal is expected to close in the third quarter of the year.
Full Content: Fox Business
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
FTC v. Meta Trial Turns to Market Definition
Apr 28, 2025 by
CPI
Marriott to Acquire CitizenM for $355 Million, Expanding Urban Lifestyle Offerings
Apr 28, 2025 by
CPI
Thomson Reuters Urges Third Circuit to Block Ross Intelligence’s Copyright Appeal
Apr 28, 2025 by
CPI
Merck KGaA to Acquire SpringWorks for $3.9 Billion
Apr 28, 2025 by
CPI
Federal Judge Dismisses Mario Chalmers’ Antitrust Lawsuit Against NCAA Over NIL Rights
Apr 28, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Mergers in Digital Markets
Apr 21, 2025 by
CPI
Catching a Killer? Six “Genetic Markers” to Assess Nascent Competitor Acquisitions
Apr 21, 2025 by
John Taladay & Christine Ryu-Naya
Digital Decoded: Is There More Scope for Digital Mergers In 2025?
Apr 21, 2025 by
Colin Raftery, Michele Davis, Sarah Jensen & Martin Dickson
AI In the Mix – An Ever-Evolving Approach to Jurisdiction Over Digital Mergers in Europe
Apr 21, 2025 by
Ingrid Vandenborre & Ketevan Zukakishvili
Antitrust Enforcement Errors Due to a Failure to Understand Organizational Capabilities and Dynamic Competition
Apr 21, 2025 by
Magdalena Kuyterink & David J. Teece